跳至主要内容
临床试验/NCT01683981
NCT01683981Unknown早期 1 期

Exercise Capacity and Quality of Life in Patients With Idiopathic Pulmonary Hypertension and Eisenmenger Syndrome Receiving Short Term Oral L-Citrulline Malate

Masih Daneshvari Hospital1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2012年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
发起方
入组人数
25
试验地点
1
主要终点
the change in exercise capacity

研究概览

简要总结

Due to vasodilatory properties of the NO, one of the therapeutic approaches for IPAH is oral use of nitric oxide precursors (10). Efficacy of L-arginine is well-documented in the current literature but there is paucity of data with regard to L-citrulline- malate. Hence, this study will evaluate therapeutic efficacy of L-citrulline- malate in two categories of patients with pulmonary hypertension (IPAH, and Eisenmeger syndrome). This randomized clinical trial utilizes 6-minute walk, pro BNP levels and the echocardiographic indexes an indicator of functional improvement of the patients.

详细描述

Pulmonary vascular tone is maintained by the action of vasoprotective compounds including nitric oxide (NO)(1).NO can be synthesized endogenously in the body via L-arginine and NOS-independent mechanism from the anion nitrite (NO2-)(2,3).Nitric oxide (NO) causes cyclic guanosine monophosphate-mediated vasodilatation of the pulmonary vasculature. Endogenous NO is also produced from the metabolism of citrulline; an amino acid generated by the urea cycle (4). NO is critical for normal development of the pulmonary vasculature and loss of this vasodilator factor and subsequent endothelial dysfunction is proposed as one of the possible explanations for development of pulmonary hypertension (1).

From a clinical standpoint, pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD).Its presence is associated with shorter survival and worse clinical outcome. In a setting of COPD, pulmonary hypertension tends to be of moderate severity and progresses slowly. Recent investigations have demonstrated endothelial dysfunction and changes in the expression of endothelial-derived mediators that regulate vascular tone and cell growth in the pulmonary arteries of patients with mild disease(5). Pulmonary vascular involvement from congenital heart disease like Eisenmeger syndrome is another important category of patients with PAH. In this congenital disease pulmonary vascular involvement follows a period in which pulmonary resistance is low and pulmonary blood flow is high (6, 7, 8). Finally, Idiopathic pulmonary hypertension (IPAH) is the third category of these patients. IPAH has unknown etiology and is characterized by progressive obliteration of small and medium size pulmonary arteries; elevation in pulmonary arterial pressure, and an increase in pulmonary vascular resistance. Presence of these pathologies eventually leads to right heart failure and death (9).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
盲法
None

入排标准

年龄范围
15 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • all patients less than 70 years old,
  • patients with a six-minute walking distance of more than 100 meters (m),
  • a mean pulmonary arterial pressure (PAP) ≥ 25 mmHg at rest as assessed by right heart catheterization(RHC) (11,12).

排除标准

  • all patients more than 70 years old,
  • patients with a six-minute walking distance of less than 100 meters (m), active pulmonary or extra pulmonary infection,
  • serious coronaropathy and/ or ventricular dysfunction,
  • significant renal illness and/or hepatitis,
  • detected immunosuppressive illnesses,
  • carrier of known neoplasias,
  • pregnancy,
  • lack of family support,
  • psychosocial problems,
  • drug or alcohol abuse, and
  • noncompliance with established medical protocol.

研究组 & 干预措施

L-Citrulline, Exercise Capacity

Experimental

L-Citrulline malate, 1gr, oral, divided 3 times a day,for 2 weeks

干预措施: L-Citrulline Malate (Drug)

结局指标

主要结局

the change in exercise capacity

时间窗: 2 weeks

The primary measure of efficacy was the change in exercise capacity, as measured by the total distance walked in six minutes, from baseline to week 2. (15)

次要结局

  • changes in mean pulmonary-artery pressure(2 weeks)

研究者

发起方
Masih Daneshvari Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

babak sharif kashani

Head of Cardiology Department of NRITLD, Associate Professor

Masih Daneshvari Hospital

研究点 (1)

Loading locations...

相似试验